Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 258-081-5 | CAS number: 52663-87-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
A 28 day oral toxicity study performed according to OECD Guideline 407 and under GLP with Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6 is available, with reliability rating 1. Based on the absence of functional or morphological disturbances supporting the changes noted in the study, a NOAEL of > 1000 mg/kg was established.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The study is performed according to OECD 407 guideline and under GLP and has reliability rating 1. It is sufficient to cover the information requirements in Annex VIII.
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
A 28-day oral toxicity study according to OECD 407 has been performed on Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6. The dose levels tested were 1000 mg/kg/day, 300 mg/kd/day and 50 mg/kg/day. This study was performed according to the current OECD 407 and EU method B7 protocols, with full GLP compliance and a well-defined test substance. No adverse effects were found in the study. The histopathology showed that the statistically higher thymus weight seen in females at 1000 mg/kg were minor, non-adverse, treatment-related lymphocytolysis. Since lymphocytolysis is a common background finding and based on the incidence, degree and lack of clear dose-relation seen in this study, this finding was not considered to be an adverse effect of the test item.
The parental toxicity effects reported in as 2-generation reproduction study on rats (parental dosing for 16 weeks) are consistent with the effects reported in the other repeat dose studies on these primary amine alaninates. The liver changes are indicative of metabolic processes and the results are also consistent with alklyamines suggesting similar toxicological mechanisms
The minimal
lymphoid hyperplasia in the mesenteric lymph nodes of the males and the
remaining microscopic findings recorded were within the normal range of
background pathology encountered in Wistar(Han) rats of this age and
strain. No adverse toxicity findings were observed up to the highest
dose level tested, and a NOAEL value could therefore not be defined. The
highest dose tested is therefore reported as NOAEL value for these this
endpoint, since the use of ">" is not possible in the IUCLID filed
specified for effect level.
The data from the 28 day oral toxicity study is therefore used to determine the DNEL values for oral, inhalation and dermal exposure following the ECHA guidance document for deriving DNEL values. As appropriate DNEL values can be calculated using the oral dosing study data, and due to the low vapour pressure of the substance, it is not justified on animal welfare grounds to perform repeat dose dermal or inhalation toxicity studies.
Work on analogue substances reviewed include further repeat dose oral testing (including dosing for reproduction tests) and these confirm low chronic toxicity with effects generally linked to liver function and some effects on kidneys. These have been considered in some cases to be adaptive and indicate metabolic processes.
This EPA study is considered valid in terms of grouping of substances. Examination of data on various primary alkylamines show little difference in repeat toxicity effects, including reproduction. Read-across is considered valid as the results are consistent with the findings in the more recent 28 days study (key study); this study show more adverse effects and is therefore considered a suitable surrogate for the reporting of reproductive effects.
The similarity in findings with the work on primary amines further justifies read-across to these potential metabolites. This is reviewed in the assessment report attached in Section 13.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
The only available 28-day oral toxicity study on Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6, is performed according to OECD 407 guideline under GLP conditions and has reliability rating 1. No adverse effects were seen in any of the selected doses in the study, and a NOAEL value could therefore not be defined. The highest dose tested is therefore reported as NOAEL value for this endpoint and used for DNEL derivation, since the use of ">" is not possible in the IUCLID filed specified for effect level below.
Justification for selection of repeated dose toxicity inhalation - systemic effects endpoint:
There is no repeat dose inhalation study Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6, however the substance is a paste with a low vapour pressure of < 1.5 mPa at 20°C. Significant exposure to vapours would not be expected at ambient temperatures so it is considered to not be scientifically valid to conduct a repeat dose inhalation study.
Justification for selection of repeated dose toxicity inhalation - local effects endpoint:
There is no repeat dose inhalation study Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6, however the substance is a paste with a low vapour pressure of < 1.5 mPa at 20°C. Significant exposure to vapours would not be expected at ambient temperatures so it is considered to not be scientifically valid to conduct a repeat dose inhalation study.
Justification for selection of repeated dose toxicity dermal - systemic effects endpoint:
There is no repeat dose dermal study Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6, but a 28 day oral toxicity study according to OECD 407 is available. Based on the physicochemical properties of the substance, it is considered very unlikely that dermal absorption would exceed oral absorption, so it would be expected than the oral NOAEL would be lower than a corresponding value from a dermal study. Results from the two acute toxicity tests available on the substance show no differences in toxicological profile, LD50 is > 2000 mg/kg bw for both exposure routes. Data from the repeat dose oral study can be used in the setting of DNELs in accordance with the REACH guidelines. As appropriate DNEL values can be calculated using the oral dosing study data, it is not justified on animal welfare grounds to perform a repeat dose dermal toxicity study.
Justification for selection of repeated dose toxicity dermal - local effects endpoint:
There is no repeat dose dermal study Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6, but all three acute skin irritation / corrosion studies and the one acute dermal toxicity study in combination with the 28 day oral toxicity study indicates low toxicity of the substance. This does not justify the requirement for an additional dermal animal study to establish a local NOAEL for dermal exposure.
Justification for classification or non-classification
The EU CLP (GHS) criteria for classification for Specific Target Organ Toxicity (STOT) are based on data from a 90 day study, for Category 2 the range for such effects is 10-<100 mg/kg/day. Where the data are from a 28 day study these levels are multiplied by three. However there were no indications of any specific systemic toxic effects such as serious organ damage in any of the dose groups of Sodium N-(2-carboxyethyl)-N-(2-ethylhexyl)-β-alaninate, CAS No 94441-92-6. Based on the lack of findings from the available 28 day oral toxicity study, there is no evidence of relevant specific target organ toxicity in the rats dosed at up to the highest dose level of 1000 mg/kg/day. Therefore it does not have to be classified and has no obligatory labelling requirement according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2011), nor the Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.